Literature DB >> 7902202

Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients.

S Uchino1, H Tsuda, K Maruyama, T Kinoshita, M Sasako, T Saito, M Kobayashi, S Hirohashi.   

Abstract

BACKGROUND: Overexpression of c-erbB-2 protein in breast cancer has been reported to be associated with poor prognosis. However, clinical significance of c-erbB-2 protein overexpression has not been demonstrated clearly in gastric cancer.
METHODS: Immunohistochemical reactivity to c-erbB-2 protein was examined in formalin-fixed, paraffin-embedded tissue sections from patients with gastric cancer.
RESULTS: First, primary stomach cancers in 106 patients were examined. Among 58 cases of papillary or well- to moderately differentiated tubular adenocarcinoma, staining of c-erbB-2 protein was positive on the plasma membrane of cancer cells in 8 cases (14%). Conversely, among 47 cases of poorly differentiated adenocarcinoma or signet ring cell carcinoma, positive staining of c-erbB-2 protein was detected in one case only (2%), where the histopathologic type was poorly differentiated adenocarcinoma with a cohesive structure. Among tubular adenocarcinomas, no significant association was shown between overexpression of c-erbB-2 protein and the depth of tumor invasion, extent of lymph node metastasis, or tumor location. To investigate the correlation between the staining of c-erbB-2 protein and prognosis in gastric cancer, an additional 108 cases of papillary or well- to moderately differentiated tubular adenocarcinoma invasive as far as the muscularis propria were examined immunohistochemically for expression of c-erbB-2 protein. Twelve cases (11%) showed positive staining on the plasma membrane, and their survival curve showed a significantly poorer prognosis (P < 0.01).
CONCLUSIONS: These results suggest that overexpression of c-erbB-2 protein occurs selectively in cohesive gastric cancer, and it can be considered an important prognostic indicator.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902202     DOI: 10.1002/1097-0142(19931201)72:11<3179::aid-cncr2820721108>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  46 in total

Review 1.  EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?

Authors:  Shailender Singh Kanwar; Jyoti Nautiyal; Adhip P N Majumdar
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

2.  Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe.

Authors:  Alexander R Novotny; Christoph Schuhmacher; Raymonde Busch; Michael W Kattan; Murray F Brennan; Jörg Rüdiger Siewert
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

3.  Mucin phenotype of gastric cancer and clinicopathology of gastric-type differentiated adenocarcinoma.

Authors:  Tsutomu Namikawa; Kazuhiro Hanazaki
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

4.  Study of differential polymerase chain reaction of C-erbB-2 oncogene amplification in gastric cancer.

Authors:  Feng Ji; Qing-Bi Peng; Jing-Biao Zhan; You-Ming Li
Journal:  World J Gastroenterol       Date:  1999-04       Impact factor: 5.742

5.  Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers.

Authors:  Meltem Baykara; Mustafa Benekli; Ozgur Ekinci; Sultan Cigdem Irkkan; Halit Karaca; Umut Demirci; Muhammed Bulent Akinci; Olcun Umit Unal; Faysal Dane; Fatma Paksoy Turkoz; Ozan Balakan; Eylem Pinar Eser; Selcuk Cemil Ozturk; Metin Ozkan; Berna Oksuzoglu; Alper Sevinc; Necla Demir; Hakan Harputluoglu; Bulent Yalcin; Ugur Coskun; Aytug Uner; Ahmet Ozet; Suleyman Buyukberber
Journal:  J Gastrointest Surg       Date:  2015-07-16       Impact factor: 3.452

6.  Letter in response to "Our HER2 is same as yours".

Authors:  Satoshi Matsusaka; Kazuhiro Yoshida
Journal:  Transl Gastroenterol Hepatol       Date:  2016-03-16

7.  Prognostic significance of HER2/neu expression in gastric cancer.

Authors:  Julian Ananiev; Maya Gulubova; Irena Manolova; Georgi Tchernev
Journal:  Wien Klin Wochenschr       Date:  2011-07-11       Impact factor: 1.704

Review 8.  Role of the tumor microenvironment in the pathogenesis of gastric carcinoma.

Authors:  Hye Won Chung; Jong-Baeck Lim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

9.  Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

Authors:  M A Gordon; H M Gundacker; J Benedetti; J S Macdonald; J C Baranda; W J Levin; C D Blanke; W Elatre; P Weng; J Y Zhou; H J Lenz; M F Press
Journal:  Ann Oncol       Date:  2013-03-22       Impact factor: 32.976

10.  HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.

Authors:  Josef Rüschoff; Manfred Dietel; Gustavo Baretton; Susanne Arbogast; Axel Walch; Geneviéve Monges; Marie-Pierre Chenard; Frédérique Penault-Llorca; Iris Nagelmeier; Werner Schlake; H Höfler; H H Kreipe
Journal:  Virchows Arch       Date:  2010-07-28       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.